Status:
ACTIVE_NOT_RECRUITING
Total Body Irradiation and Cladribine Before Allogeneic Hematopoietic Cell Transplantation in Patients With AML (Acute Myeloid Leukemia) and Myelodysplastic Syndromes
Lead Sponsor:
Maria Sklodowska-Curie National Research Institute of Oncology
Collaborating Sponsors:
KCRI
Conditions:
Acute Myeloid Leukemia Myelodysplastic Syndromes
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
A single center, prospective, one arm clinical study to assess the tolerance and effectiveness of total body irradiation and cladribine in adult patients diagnosed with AML( acute myeloid leukemia) an...
Eligibility Criteria
Inclusion
- Age between 18 and 60 years.
- Patient is a candidate for allogeneic hematopoietic cell transplantation due to acute myeloid leukemia(intermediate or high risk acute myeloid leukemia in complete remission, low risk with positive Minimal residual disease) or high risk myelodysplastic syndrome.
- Demonstration of chemosensitivity in the case of treatment regimens with cladribine in induction therapy.
- Patient signed informed consent form prior to any study related screening procedures are performed.
- Patient has Eastern Cooperative Oncology Group performance status score of 0 or 1.
- Patient is a candidate for allogeneic hematopoietic cell transplantation from sibling or unrelated donor (full matched or 9/10 mismatched) or from haploidentical donor.
Exclusion
- Has received more than 1 allogeneic hematopoietic cell transplantation.
- Presence of active uncontrolled infection (i.e. sepsis, new symptoms, worsening physical signs or radiographic findings attributable to infection).
- Known active human immunodeficiency virus, hepatitis B virus or hepatitis C virus infection (positive polymerase chain reaction test) or risk of hepatitis B virus reactivation (Hepatitis B surface antigen positive).
- Presence of active disease in acute myeloid leukemia patients.
- History or current diagnosis for uncontrolled or significant cardiac or pulmonary disease.
- Presence of severe renal or liver dysfunction (creatinine, alanine aminotransferase,aspartate aminotransferase or bilirubin concentration \> 3.0 upper limit of normal
- Currently pregnancy or breast feeding.
- Treatment of any other investigational agent in the same time as this study.
- Known allergies, hypersensitivity, or intolerance to cladribine or similar compounds.
- Women of childbearing potential who do not agree to use two effective methods of contraception.
Key Trial Info
Start Date :
October 7 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04861207
Start Date
October 7 2021
End Date
December 31 2027
Last Update
April 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Klinika Transplantacji Szpiku i Onkohematologii Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy, Oddział w Gliwicach
Gliwice, Poland, 44-101